**Core tip:** Targeted next-generation sequencing was used to detect gene mutations rather than mutational hotspots in the present study. This manuscript is by far the first to report the predictive value of the combined mutation status of *PIK3CA* and *TP53* in colorectal cancer patients receiving 5-FU-based adjuvant chemotherapy. Our data revealed that the double mutation of *PIK3CA* and *TP53* is an independent predictive factor for overall survival in stage II/III patients receiving 5-FU-based chemotherapy.

INTRODUCTION
============

Colorectal cancer (CRC) is now the third most common cancer worldwide\[[@B1]\]. The genesis of colorectal cancer is a multi-step, multi-gene process, receiving a great deal of interactive influence from genetic and environmental factors. Attributed to advancements in surgical techniques and the popularization of chemotherapy and targeted therapy, the treatment of CRC has rapidly evolved over several decades. 5-fluorouracil (5-FU)-based adjuvant chemotherapy is regarded as a first-line chemotherapy in both adjuvant and palliative settings for advanced CRC. Regrettably, however, a considerable number of patients not only fail to show an objective response to first-line chemotherapy treatment but also suffer from side effects\[[@B2],[@B3]\]. Hence, studies of the biomarkers related to clinical outcome are in urgent demand as a way to identify whether patients benefit from adjuvant chemotherapy.

At present, the response rate of CRC patients receiving 5-FU-based adjuvant thermotherapy is approximately 40%-50%\[[@B3]-[@B7]\], and despite much research on the prediction of response, it has not been possible to identify a predictive biomarker as an indicator of the likely benefit in patients receiving 5-FU-based adjuvant chemotherapy. Thus, an early, quick, efficient, and accurate method is of great clinical significance and value to identify new predictive markers.

It is widely known that the multi-drug resistance (MDR) to anticancer drugs is the main cause of chemotherapy failure. Recent studies have indicated that activation of the PI3K/AKT signaling pathway can result in disturbance of cellular growth, proliferation, and survival in a variety of solid tumors\[[@B8]\] and can cause MDR of cancer cells through multiple mechanisms\[[@B9]\]. It is well documented that the effect of the aberrant regulation of the PI3K/AKT signaling pathway on cell growth and apoptosis induced by anti-cancer drugs was observed *in vitro* and *in vivo*\[[@B10]-[@B14]\]. Given the role of the PI3K/AKT signaling pathway in the development of resistance to anticancer drugs, it is conceivable that genetic mutations (such as *PIK3CA*) in the molecules of the PI3K/AKT signaling pathway could be a promising predictive biomarker for chemotherapy efficacy. *TP53*, the widely studied tumor suppressor gene which has an intimate connection with the occurrence and progression of many tumors in humans, mainly regulates several cellular processes, including cell cycle regulation, DNA repair, and apoptosis\[[@B15],[@B16]\]. Multiple studies have bolstered the notion that *TP53* is correlated with the drug resistance of tumor cells and could emerge as a biomarker with predictive value and potential clinical utility\[[@B17]-[@B20]\]. Thus, we proposed that *PIK3CA* and *TP53* mutation status is likely well associated with clinical outcome in patients undergoing chemotherapy.

In the present study, we evaluated the predictive value of *PIK3CA* and *TP53* mutation status in CRC patients undergoing 5-FU-based chemotherapy after curative surgery and identified subgroups of patients who greatly benefited from specific treatment regimens.

MATERIALS AND METHODS
=====================

Study population
----------------

In this study, a total of 315 patients with histologically proven CRC were enrolled from Yangpu Hospital affiliated to Shanghai Tongji University between 2007 and 2011. Among these patients, 241 with stage II/III CRC received 5-FU-based adjuvant chemotherapy as a first-line treatment for at least six cycles. Tumor staging was strictly abided by the TNM classification of the American Joint Committee on Cancer. Formalin-fixed paraffin-embedded (FFPE) lesion samples of the patients with curatively resected CRC were collected from the pathology department where the primary colorectal tumors from the patients in this study were preserved. Histopathological diagnosis by an experienced pathologist was performed for all tissue samples, and at least 70% of tumor cells could be observed in the whole section through light microscopy. Any case that did not meet the experimental standard was excluded from this study. The clinicopathological features, including pathologic stage, tumor location, and date of diagnosis and death, were collected. The definition of proximal colon cancer included the cecum and ascending and transverse colon, while tumors located in the splenic flexure and descending and sigmoid colon were characterized as distal colon cancer, and the rectum was defined from the rectosigmoid junction (the end of the sigmoid colon) to the dentate line. Written informed consent was obtained from all participants at the time of study enrollment. This study was approved by the Medical Ethics Committee of Yangpu Hospital.

DNA extraction and targeted next-generation sequencing
------------------------------------------------------

Genomic DNA was extracted from FFPE sections of the 315 tumors. The 10-μm-thick sections were subjected to standard deparaffinization procedures and proteinase K digestion overnight. Genomic DNA was isolated using a QIAamp DNA FFPE Tissue kit (Qiagen). All extracted DNA was quantified with a Qubit 3.0 fluorometer (Thermo Fisher Scientific) and Bioanalyzer 2100 (Agilent) before targeted next-generation sequencing\[[@B21],[@B22]\].

Next-generation mutational analysis was performed using an Ion Torrent platform (Thermo Fisher Scientific) in CRC and matched normal tissues of 315 patients to identify somatic gene mutation profile. DNA library was generated using an Ion AmpliSeq DNA library kit (Thermo Fisher Scientific). According to the manufacturer's protocols, 10 ng of DNA was used as the template to amplify targets with sequencing primer panel (Thermo Fisher Scientific). Amplified targets were digested with Fupa enzyme and subsequently ligated with adapters. The library was quantified with a quantitative PCR kit and loaded into chips in Ion Chef (Thermo Fisher Scientific). The chips were loaded into an Ion S5 XL sequencer (Thermo Fisher Scientific) for sequencing. Sequencing data were processed and analyzed on a bioinformatics analysis server termed as Ion Reporter (Thermo Fisher Scientific)\[[@B23]\].

Statistical analysis
--------------------

The study endpoint was overall survival (OS), which was calculated from pathologic diagnosis to death, regardless of cause. All statistical analyses were performed using Stata software (version 14.2). We used Cox proportional hazards models to estimate the hazard ratios (HRs) of survival adjusted for baseline patient variables. The Kaplan-Meier method was performed to generate a survival curve, with significance evaluated using a log-rank test. Where appropriate, categorical and continuous variables were estimated by the χ^2^ test. *P* \< 0.05 was considered statistically significant.

RESULTS
=======

Patient characteristics
-----------------------

Altogether, 315 CRC patients were enrolled in this study; 14.6% (*n* = 46) of them had stage I CRC, while 40.6% (*n* = 128), 35.9% (*n* = 113), and 8.9% (*n* = 28) had stages II, III, and IV CRC, respectively. The clinicopathological features of the study population are summarized in Table [1](#T1){ref-type="table"}. Genomic DNA from FFPE lesion samples of the patients with curatively resected CRC was screened for somatic mutations in the *PIK3CA* and *TP53* genes. Among the 315 patients, the incidence of *PIK3CA* and *TP53* mutations was 38.4% (*n* = 121) and 65.1% (*n* = 205), respectively, while wild type was detected in 61.6% (*n* = 194) and 34.9% (*n* = 110), respectively. In the study cohort, *PIK3CA*-mutated tumors were significantly correlated with proximal location (*P* = 0.036), while *TP53*-mutated tumors were not significantly associated with any examined clinical features. The frequency of *PIK3CA* mutations in the proximal, distal, and rectum location was 50% (39/78), 38.7% (29/75), and 32.7% (53/162), respectively.

###### 

Patient demographics and disease characteristics *n* (%)

  **Clinicopathological feature**   ***PIK3CA***   ***P* value**   ***TP53***   ***P* value**   **Both *PIK3CA* and *TP53* wild-type**   **Both *PIK3CA* and *TP53* mutation**   **Others**   ***P* value**                
  --------------------------------- -------------- --------------- ------------ --------------- ---------------------------------------- --------------------------------------- ------------ --------------- ------------ -------
  Age (yr)                                                                                                                                                                                                                 
  \< 60                             52 (26.80)     29 (23.97)                   31 (28.18)      50 (24.39)                                                                       26 (31.33)   22 (28.57)      33 (21.29)   
  60-70                             47 (24.23)     33 (27.27)                   28 (25.45)      52 (25.37)                                                                       20 (24.10)   18 (23.38)      42 (27.10)   
  ≥ 70                              95 (48.97)     59 (48.76)      0.776        51 (46.36)      103 (50.24)                              0.733                                   37 (44.58)   37 (48.05)      80 (51.61)   0.500
  Sex                                                                                                                                                                                                                      
  Male                              107 (55.15)    73 (60.33)                   67 (60.91)      113 (55.12)                                                                      47 (56.63)   45 (58.44)      88 (56.77)   
  Female                            87 (44.85)     48 (39.67)      0.367        43 (39.09)      92 (44.88)                               0.322                                   36 (43.37)   32 (41.56)      67 (43.23)   0.965
  Tumor location                                                                                                                                                                                                           
  Rectum                            109 (56.19)    53 (43.80)                   53 (48.18)      109 (53.17)                                                                      48 (57.83)   41 (53.25)      73 (47.10)   
  Proximal                          39 (20.10)     39 (32.23)                   32 (29.09)      46 (22.44)                                                                       17 (20.48)   19 (24.68)      42 (27.10)   
  Distal                            46 (23.71)     29 (23.97)      0.036        25 (22.73)      50 (24.39)                               0.426                                   18 (21.69)   17 (22.08)      40 (25.81)   0.601
  Stage T                                                                                                                                                                                                                  
  T1-T2                             34 (17.53)     26 (21.49)                   20 (18.18)      40 (19.51)                                                                       15 (18.07)   16 (20.78)      29 (18.71)   
  T3                                38 (19.59)     19 (15.70)                   21 (19.09)      36 (17.56)                                                                       17 (20.48)   11 (14.29)      29 (18.71)   
  T4                                122 (62.89)    76 (62.81)      0.539        69 (62.73)      129 (62.93)                              0.923                                   51 (61.45)   50 (64.94)      97 (62.58)   0.884
  Stage N                                                                                                                                                                                                                  
  N0                                118 (60.82)    70 (57.85)                   68 (61.82)      120 (58.54)                                                                      53 (63.86)   45 (58.44)      90 (58.06)   
  N1                                55 (28.35)     35 (28.93)                   28 (25.45)      62 (30.24)                                                                       20 (24.10)   23 (29.87)      47 (30.32)   
  N2                                21 (10.82)     16 (13.22)      0.785        14 (12.73)      23 (11.22)                               0.656                                   10 (12.05)   9 (11.69)       18 (11.61)   0.889
  Stage                                                                                                                                                                                                                    
  I                                 23 (11.86)     23 (19.01)                   16 (14.55)      30 (14.63)                                                                       12 (14.46)   14 (18.18)      20 (12.90)   
  II                                86 (44.33)     42 (34.71)                   47 (42.73)      81 (39.51)                                                                       37 (44.58)   28 (36.36)      63 (40.65)   
  III                               70 (36.08)     43 (35.54)                   38 (34.55)      75 (36.59)                                                                       27 (32.53)   26 (33.77)      60 (38.71)   
  IV                                15 (7.73)      13 (10.74)      0.166        9 (8.18)        19 (9.27)                                0.948                                   7 (8.43)     9 (11.69)       12 (7.74)    0.774

Among the 241 patients with stage II/III disease in this cohort, the *PIK3CA* and/or *TP53* mutation was detected in 177 patients, of whom 54 had *PIK3CA* and *TP53* double mutations. As reported in Table [1](#T1){ref-type="table"}, mutation status of the *PIK3CA* and *TP53* genes was comparable according to baseline characteristics. No significant difference was observed between these variables and baseline characteristics (Table [1](#T1){ref-type="table"}).

For individual sites of *PIK3CA* mutation, the most frequent mutation in CRC was the mutation of Glu545Lys (5.1%), followed by Glu542Lys (2.2%). The most frequent *TP53* mutations included: Arg175His (5.1%), Arg282Trp (3.5%), Gly245Ser (2.9%), and Arg248Gln (2.9%) (Table [2](#T2){ref-type="table"}).

###### 

Top ten mutations of *PIK3CA* and *TP53* in this study

  ***PIK3CA***   ***n* (%)**   ***TP53***   ***n* (%)**
  -------------- ------------- ------------ -------------
  Glu545Lys      16 (5.1)      Arg175His    16 (5.1)
  Glu542Lys      7 (2.2)       Arg282Trp    11 (3.5)
  Val105Ile      6 (1.9)       Gly245Ser    9 (2.9)
  Met1004Ile     6 (1.9)       Arg248Gln    9 (2.9)
  His1047Arg     6 (1.9)       Arg273His    8 (2.5)
  Glu218Lys      6 (1.9)       Arg273Cys    7 (2.2)
  Trp552Ter      5 (1.6)       Arg248Trp    7 (2.2)
  Ser438Phe      5 (1.6)       Ser260Phe    6 (1.9)
  Pro835Leu      5 (1.6)       Glu358Lys    6 (1.9)
  Asp1029Asn     5 (1.6)       Pro153Ser    5 (1.6)

***Predictive value of PIK3CA or TP53 mutation in stage*** II***/***III ***CRC patients***

All stage II/III CRC patients (*n* = 241) received 5-FU-based adjuvant chemotherapy for at least six cycles as first-line treatment after operation. In univariate and multivariate analyses, neither *PIK3CA* nor *TP53* mutation was significantly correlated with patient survival (Table [3](#T3){ref-type="table"}). The Kaplan-Meier curve showed that patients harboring the *TP53* mutation had a worse clinical outcome than patients with wild-type status (Log-rank *P* = 0.046; Figure [1A](#F1){ref-type="fig"}), and no association was found between *PIK3CA* and clinical outcome (Log-rank *P* = 0.150; Figure [1B](#F1){ref-type="fig"}).

![Kaplan-Meier survival analysis for overall survival in patients with stage II/III colorectal cancer according to *TP53* mutation status (A); *PIK3CA* mutation status (B); and *PIK3CA* and *TP53* mutation status (C).](WJG-24-631-g001){#F1}

###### 

Univariate and multivariate analyses (Cox proportional hazards model) of OS for patients with stage II/III CRC treated with 5-FU-based chemotherapy according to *PIK3CA* and/or *TP53* mutation status *n* (%)

                                       **Alive**     **Dead**     **Univariate HR (95%CI)**   ***P* value**   **Multivariate HR (95%CI)**   ***P* value**
  ------------------------------------ ------------- ------------ --------------------------- --------------- ----------------------------- ---------------
  *PIK3CA*                                                                                                                                  
  Wild-type                            114 (73.08)   42 (26.92)   1 (Ref.)                                    1 (Ref.)                      
  Occasional                           5 (55.56)     4 (44.44)    1.93 (0.69-5.39)            0.208           1.40 (0.49-4.05)              0.530
  Recurrent                            48 (63.16)    28 (36.84)   1.50 (0.93-2.42)            0.096           1.29 (0.79-2.11)              0.314
  *TP53*                                                                                                                                    
  Wild-type                            63 (74.12)    22 (25.88)   1 (Ref.)                                    1 (Ref.)                      
  Occasional                           32 (80.00)    8 (20.00)    0.80 (0.35-1.79)            0.583           0.84 (0.37-1.94)              0.687
  Recurrent                            72 (62.07)    44 (37.93)   1.65 (0.99-2.76)            0.055           1.68 (0.98-2.87)              0.057
  *PIK3CA* and *TP53*                                                                                                                       
  Both *PIK3CA* and *TP53* Wild-type   49 (76.56)    15 (23.44)   1 (Ref.)                                    1 (Ref.)                      
  Both *PIK3CA* and *TP53* Mutation    31 (57.41)    23 (42.59)   2.21 (1.15-4.24)            0.017           2.02 (1.04-3.91)              0.037
  Others                               87 (70.73)    36 (29.27)   1.31 (0.72-2.40)            0.376           1.16 (0.63-2.16)              0.629

Occasional mutation was defined as a single tumor with mutation of *PIK3CA* or *TP53*, while recurrent was mutations detected in two or more tumors. HR: Hazard ratio; 95%CI: 95% confidence interval; OS: Overall survival; CRC: Colorectal cancer.

***Predictive value of double PIK3CA-TP53 mutations in stage*** II***/***III ***CRC patients***

We assessed the predictive value of double *PIK3CA-TP53* mutations for survival in stage II/III CRC patients treated with 5-FU-based chemotherapy according to the statistical results of Cox proportional hazards and Kaplan-Meier analyses. Compared with concomitant *PIK3CA* and *TP53* wild-type tumors, double *PIK3CA-TP53* mutations were a significantly poor predictive factor for OS (univariate HR = 2.21; 95%CI: 1.15-4.24; multivariate HR = 2.02; 95%CI: 1.04-3.91) (Table [3](#T3){ref-type="table"}). In contrast, no association was found between the mutational status of a single gene, either *PIK3CA* or *TP53*, and OS (*P* = 0.629; Table [3](#T3){ref-type="table"}). The Kaplan-Meier curve showed a shorter OS in patients harboring double *PIK3CA* and *TP53* mutations compared with concomitant *PIK3CA* and *TP53* wild-type patients (Log-rank *P* = 0.034; Figure [1C](#F1){ref-type="fig"}).

***Association of PIK3CA mutation in a functional domain with clinical outcome in stage*** II***/***III ***CRC patients***

In the multivariable analysis of the association of *PIK3CA* functional domain mutation with OS, no significant difference was observed. The results of multivariable analysis are shown in Table [4](#T4){ref-type="table"}. As suggested by the results, the *PIK3CA* mutation located in the kinase domain showed a trend toward a shorter OS compared with wild-type tumors (multivariate HR = 1.56; 95%CI: 1.00-2.44; *P* = 0.052). The Kaplan-Meier curve showed that patients harboring the *PIK3CA* mutation located in the kinase domain had a worse clinical outcome than those with wild-type status (Log-rank *P* = 0.041; Figure [2](#F2){ref-type="fig"}).

![Kaplan-Meier survival analysis for overall survival according to the *PIK3CA* kinase domain mutation status in stage II/III patients.](WJG-24-631-g002){#F2}

###### 

Association of *PIK3CA* functional domain mutations with overall survival in stage II/III CRC patients *n* (%)

  **Domain**           **Alive**     **Dead**     **Multivariate HR (95%CI)**   ***P* value**
  -------------------- ------------- ------------ ----------------------------- ---------------
  Kinase domain                                                                 
  Wild-type            116 (60.42)   76 (39.58)   1 (Ref.)                      
  Mutation             23 (46.94)    26 (53.06)   1.56 (1.00-2.44)              0.052
  C2 domain                                                                     
  Wild-type            118 (58.71)   83 (41.29)   1 (Ref.)                      
  Mutation             21 (52.50)    19 (47.50)   1.13 (0.68-1.86)              0.638
  Helical domain                                                                
  Wild-type            110 (59.14)   76 (40.86)   1 (Ref.)                      
  Mutation             29 (52.73)    26 (47.27)   1.30 (0.83-2.05)              0.248
  p85 binding domain                                                            
  Wild-type            127 (57.73)   93 (42.27)   1 (Ref.)                      
  Mutation             12 (57.14)    9 (42.86)    1.05 (0.53-2.08)              0.894
  Ras binding domain                                                            
  Wild-type            123 (58.57)   87 (41.43)   1 (Ref.)                      
  Mutation             16 (51.61)    15 (48.39)   1.27 (0.73-2.20)              0.404

HR: Hazard ratio; 95%CI: 95% confidence interval.

DISCUSSION
==========

CRC is one of the most common malignancies. Despite much research on biomarkers in patients with cancer, the number of biomarkers with predictive value and potential clinical utility is pitifully small\[[@B24]-[@B27]\]. Moreover, co-occurring genetic alterations have been detected in multiple malignancies\[[@B28]\]. In the present study, we evaluated two biomarkers with predictive value to identify subgroups of patients who would greatly benefit from 5-FU-based chemotherapy. We found that the double mutation of *PIK3CA* and *TP53* was greatly associated with worse clinical outcomes in 241 stage II/III CRC patients receiving 5-FU-based adjuvant chemotherapy. In contrast, mutations in *PIK3CA* or *TP53* alone had no effect on the OS of CRC patients.

Although mutations in these two genes have been widely researched, the present study is by far the first to report the predictive role of the combined mutation status of *PIK3CA* and *TP53* in CRC patients. Targeted next-generation sequencing was used to detect gene mutations rather than mutational hotspots in the present study. The frequencies of *PIK3CA* and *TP53* mutations were 35% (85/241) and 65% (156/241), respectively, which are consistent with previously published studies reporting *PIK3CA* and *TP53* mutations in 10%-32% and 40%-60% of CRC patients, respectively, in Western studies\[[@B29]-[@B32]\]. The present results are consistent with those of two previous studies, showing that the proximal colon showed a higher frequency of *PIK3CA* mutations than any other sites\[[@B33],[@B34]\].

Several studies on the predictive roles of the *PIK3CA* mutation for response have been published\[[@B35]-[@B37]\]. A meta-analysis showed that the *PIK3CA* mutation in *KRAS* wild-type patients with metastatic CRC could predict responses to anti-EGFR monoclonal antibody therapy\[[@B38]\], while another study identified the *PIK3CA* mutation in exon 20\[[@B39]\]. Moreover, recent studies have suggested that the *PIK3CA* mutation might serve as a predictive biomarker for adjuvant aspirin therapy in CRC\[[@B40],[@B41]\]. Thus, the *PIK3CA* mutation has a plausible role as a predictive marker for response to drugs. In clinical studies, there was no evidence that a mutation in *PIK3CA* was associated with 5-FU-based treatment benefits in colorectal cancer\[[@B42]\]. The present results are consistent with those of a previous study, showing that *PIK3CA* was limited as a marker for predicting responses to 5-FU-based treatment in CRC.

The inactivation of tumor suppressor genes plays a key role in tumorigenesis\[[@B43]\]. Obviously, the detection of *TP53* status in view of one of the most common tumor suppressor genes is important in the research of cancer\[[@B44]\]. *TP53* could serve as a potential biomarker for prognosis with potential predictive value and clinical utility. However, the controversial results of the available literature make it difficult to achieve a chorus of approval\[[@B45]-[@B49]\]. Several studies have shown that the *TP53* status was an independent predictive factor for responses to 5-FU\[[@B47],[@B50],[@B51]\], although other studies showed null association\[[@B46]\]. Many reasons account for these discrepant results, such as lack of reproducibility, underpowered robust statistical analysis, poor study design, and general methodological differences. There is no consensus on whether or not *TP53* emerges as a critical selection criterion to predict chemotherapy efficacy in CRC patients. Interestingly, our results showed that no association was found between clinical outcome and *TP53* status in univariate and multivariate analyses. Based on the results of the Kaplan-Meier curve, patients with wild-type *TP53* had a significantly prolonged survival compared to those harboring the *TP53* mutation.

The effect of a single gene variation as a predictive biomarker is often modest, but sometimes an additive or powerful predictive effect can be achieved by combining multiple gene alterations with the same function. Indeed, gene alteration of *PIK3CA* or *TP53* can result in cell apoptosis and drug-resistance of tumor cells through activating specific signaling pathways. Recent studies have reported that *PIK3CA* expression was correlated with the expression of *MDR-1* (encoding the MDR-associated protein P-glycoprotein)\[[@B52],[@B53]\]. Additionally, the up-regulation of *MRP-1* (encoding the MDR-associated protein) induced by the activation of PI3K could cause the chemoresistance of cells in prostatic carcinomas\[[@B54]\]. This same regulatory mechanism also occurred in *TP53*, as studies have shown that wild-type *TP53* could serve as a negative regulator of both *MDR-1* and *MRP-1*\[[@B18],[@B55]\], implicating potential associations of combined *PIK3CA* and *TP53* with clinical outcomes to comprehend the value of their combination in predicting the benefit of patients receiving 5-FU-based chemotherapy. Interestingly, the double mutation of *PIK3CA* and *TP53* has previously been correlated with a shorter OS. Remarkably, multivariate analysis showed that this correlation was independent of age, gender, stage, and tumor location, thereby confirming that the combined analysis of *PIK3CA* and *TP53* mutation status could become a marker to identify subgroups of patients who have a poor prognosis and provide valuable information for more clinical therapy projects.

The *PIK3CA* gene is divided into five functional domains: p85 binding domain, Ras binding domain, C2 domain, helical domain, and kinase domain\[[@B30]\]. The main mutation of *PIK3CA* occurs in exons 9 and 20, corresponding to the helical and kinase domains, respectively\[[@B56]\]. Recent studies have shown that patients treated with anti-EGFR monoclonal antibodies (MoAbs) and harboring *PIK3CA* mutations in exon 20 were significantly associated with worsening outcomes in KRAS wild-type mCRC\[[@B39],[@B57]\]. In the present study, the Cox proportional hazard model analysis of the effect of the *PIK3CA* mutation occurring in the kinase domain on clinical outcome reached marginally statistical significance (*P* = 0.052), whereas the Kaplan-Meier curve achieved statistical significance (Log-rank *P* = 0.041; Figure [2](#F2){ref-type="fig"}). The trend for statistical significance was evident for worsening clinical outcomes with mutations occurring in the kinase domain.

Thus far, with regard to research on *PIK3CA* or *TP53* mutations, obviously, the tumor samples of patients with CRC were collected from a single hospital in most studies, and even for many multi-centered clinical trials, patients were enrolled on the basis of epidemiological settings. Similarly, in the present study, we used tumor samples from a single hospital to reduce selection bias. Additionally, genetic heterogeneity is a reality of all tumors and is decreased by limiting the study to stage II/III patients receiving the same chemotherapy regimens. In addition, considering that a small number of total samples could lead to a less robust statistical analysis, a large sample size (*n* = 241) warranted adequate statistical power in the present study.

In conclusion, the present study suggests that the double mutation of *PIK3CA* and *TP53* is correlated with a shorter OS of stage II/III CRC patients receiving 5-FU-based therapy and hence serves as a novel biomarker to identify subgroups of patients who have poor clinical outcome, with potential clinical utility.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

5-fluorouracil (5-FU) remains one of the most effective and commonly used chemotherapeutic agents in both adjuvant and palliative settings for advanced colorectal cancer (CRC). However, many CRC patients treated with 5-FU-based adjuvant chemotherapy not only fail to show an objective response to chemotherapy treatment but also suffer from side effects. Therefore, predictive markers are in urgent demand to identify whether patients can benefit from adjuvant chemotherapy.

Research motivation
-------------------

Multiple studies have indicated that *PIK3CA* and *TP53* mutation status was correlated with drug resistance of tumor cells. By analyzing the associations between mutation status of these two genes and overall survival (OS), we may be able to identify subgroups of patients who have a poor prognosis, which can help clinicians make suitable treatment of patients.

Research objectives
-------------------

The objectives of this study were to detect gene mutations of *PIK3CA* and *TP53* by using targeted next-generation sequencing (NGS) in a large cohort of CRC patients, and to investigate the predictive value of the mutational status of *PIK3CA* and *TP53*, alone or in combination.

Research methods
----------------

A total of 315 patients with histologically proven CRC between 2007 and 2011 were retrospectively analyzed. Formalin-fixed paraffin-embedded lesion samples of the patients with curatively resected CRC were collected from the pathology department. Ten-μm-thick sections from FFPE tumor samples were used for DNA extraction with a QIAamp DNA FFPE Tissue kit (Qiagen). Targeted NGS was performed using the Ion Torrent platform to characterize the mutational spectrum of *PIK3CA* and *TP53* genes. The distribution of gene mutation according to clinicopathologic variables was analyzed using Chi-square tests. The associations between mutation status of *PIK3CA* and *TP53* and OS were evaluated using Cox proportional hazards models adjusted for clinicopathologic variables. The Kaplan-Meier method was performed to generate a survival curve, with significance evaluated using a log-rank test.

Research results
----------------

Among the 315 patients, the incidence of *PIK3CA* and *TP53* mutations was 38.4% (*n* = 121) and 65.1% (*n* = 205), respectively. A significant difference was observed in the distribution of *PIK3CA* mutations according to tumor location (*P* = 0.036). The frequency of *PIK3CA* mutations in the proximal, distal, and rectum location was 50% (39/78), 38.7% (29/75), and 32.7% (53/162), respectively. The *PIK3CA* and/or *TP53* mutation was detected in 177 out of 241 patients with stage II/III CRC receiving 5-FU-based adjuvant chemotherapy, of whom 54 had *PIK3CA* and *TP53* double mutations. In both univariate and multivariate analyses, neither *PIK3CA* nor *TP53* mutation was significantly correlated with OS. In Kaplan-Meier survival curve, patients with *TP53* mutation had a worse clinical outcome than patients with wild-type *TP53* (Log-rank *P* = 0.046). Compared with patients without *PIK3CA* and *TP53* mutations, those with double *PIK3CA-TP53* mutations had a significantly poorer OS (univariate HR = 2.21; 95%CI: 1.15-4.24; multivariate HR = 2.02; 95%CI: 1.04-3.91). In contrast, the presence of a single gene mutation, either *PIK3CA* or *TP53*, was not significantly associated with OS. The Kaplan-Meier curve showed that shorter OS was detected in patients harboring double *PIK3CA* and *TP53* mutations (Log-rank *P* = 0.034). In Kaplan-Meier survival curve, patients harboring the *PIK3CA* mutation located in the kinase domain experienced a significantly shorter OS when compared with wild-type status (Log-rank *P* = 0.041).

Research conclusions
--------------------

This study is by far the first to report the predictive role of the combined mutation status of *PIK3CA* and *TP53* in CRC patients receiving 5-FU-based adjuvant chemotherapy. Our data revealed that the double mutation of *PIK3CA* and *TP53* is correlated with a shorter OS of stage II/III CRC patients receiving 5-FU-based therapy and hence serves as a novel biomarker to identify subgroups of patients who have poor clinical outcome, with potential clinical utility.
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